Previous 10 | Next 10 |
2023-05-06 10:15:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...
2023-05-05 15:00:33 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
2023-04-28 10:03:38 ET Gainers: Tempest Therapeutics ( TPST ) +72% . CVRx ( CVRX ) +25% . ImmunoGen ( IMGN ) +22% . Apyx Medical ( APYX ) +17% . bluebird bio ( BLUE ) +17% . Losers: Hillstream BioPharma ( HILS ) -56%...
2023-04-27 23:11:05 ET Accolade, Inc. (ACCD) Q4 2023 Earnings Conference Call April 27, 2023, 04:30 PM ET Company Participants Todd Friedman - Head of Investor Relations Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nu...
2023-04-27 16:07:29 ET Accolade press release ( NASDAQ: ACCD ): FQ4 GAAP EPS of -$0.42 in-line. Revenue of $99M (+5.5% Y/Y) misses by $0.6M . For the fiscal first quarter ending May 31, 2023, we expect: Revenue between $89 million and $91 million,vs. consen...
Fiscal fourth quarter 2023 revenue of $99.0 million, a 6% increase compared to fiscal fourth quarter 2022 revenue of $93.8 million Fiscal year 2023 revenue of $363.1 million, a 17% increase compared to fiscal 2022 revenue of $310.0 million SEATTLE, April 27, 2023 (GLOBE NEWSWIRE) -- A...
Shares of Accolade, Inc. (NASDAQ: ACCD) traded at a new 52-week high today and are currently trading at $16.56. So far today, approximately 272k shares have been exchanged, as compared to an average 30-day volume of 462.6k shares. Accolade, Inc. develops and provides technology-enabled soluti...
SEATTLE, April 24, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will host an Analyst Day at the Wynn Las Vegas on May 8, 2023 and will provide a webcast of the event beginning at 1pm PT. Members o...
Shares of Accolade, Inc. (NASDAQ: ACCD) traded at a new 52-week high today and are currently trading at $14.72. So far today, approximately 192.23k shares have been exchanged, as compared to an average 30-day volume of 501.17k shares. Accolade, Inc. develops and provides technology-enabled so...
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal fourth quarter 2023 financial results on Thursday, April 27, 2023, after the market closes. In conjunction, the compan...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...